Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2024

The Pharma Closeout tracks 62 deals, $130.2B in disclosed deal value, 32 with a post-close Outcome Score for the year 2024.

Median Critic Score: 86  ·  Median Outcome Score: 64

Best outcome: Novo Holdings A/S / Catalent (manufacturing sites) (81)  ·  Weakest outcome: Novartis AG / MorphoSys AG (36)

All 62 deals

• Novo Holdings A/S / Catalent (manufacturing sites) — 2024 · $11.0B · Worked — the deal delivered on its rationale.
• Novartis AG / PTC Therapeutics Inc. — 2024 · $2.9B · Worked — the deal delivered on its rationale.
• Vertex Pharmaceuticals Inc. / Alpine Immune Sciences — 2024 · $4.9B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Shockwave Medical — 2024 · $13.1B · Worked — the deal delivered on its rationale.
• Gilead Sciences Inc. / CymaBay Therapeutics — 2024 · $4.4B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Amolyt Pharma — 2024 · $1.1B · Largely worked — most objectives met.
• Sarepta Therapeutics Inc. / Arrowhead Pharmaceuticals Inc. — 2024 · $1.1B · Largely worked — most objectives met.
• Novartis AG / PeptiDream Inc. — 2024 · $2.9B · Largely worked — most objectives met.
• Novartis AG / Shanghai Argo Biopharmaceutical Co. Ltd. — 2024 · $4.2B · Largely worked — most objectives met.
• Sanofi SA / Inhibrx Inc. — 2024 · $2.2B · Largely worked — most objectives met.
• Ono Pharmaceutical Co., Ltd. / Deciphera Pharmaceuticals — 2024 · $2.4B · Largely worked — most objectives met.
• Biogen Inc. / Human Immunology Biosciences — 2024 · $1.1B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Prime Medicine Inc. — 2024 · $3.5B · Largely worked — most objectives met.
• Johnson & Johnson / Proteologix Inc. — 2024 · $850M · Largely worked — most objectives met.
• Merck & Co. Inc. / Harpoon Therapeutics — 2024 · $680M · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / BioArctic AB — 2024 · $1.4B · Largely worked — most objectives met.
• AstraZeneca PLC / Fusion Pharmaceuticals Inc. — 2024 · $2.4B · Largely worked — most objectives met.
• Genmab A/S / ProfoundBio Inc. — 2024 · $1.8B · Largely worked — most objectives met.
• AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. — 2024 · $2.0B · Largely worked — most objectives met.
• Eli Lilly and Company / Morphic Holdings — 2024 · $3.2B · Largely worked — most objectives met.
• GSK plc / Duality Biologics (Suzhou) Co. Ltd. — 2024 · $975M · Largely worked — most objectives met.
• Merck & Co. Inc. / EyeBio Ltd. — 2024 · $3.0B · Largely worked — most objectives met.
• AbbVie Inc. / MedinCell S.A. — 2024 · $1.9B · Largely worked — most objectives met.
• Roche Holding AG / Poseida Therapeutics — 2024 · $1.5B · Largely worked — most objectives met.
• Novartis AG / Voyager Therapeutics Inc. — 2024 · $1.3B · Largely worked — most objectives met.
• GSK plc / Aiolos Bio — 2024 · $1.0B · Largely worked — most objectives met.
• AbbVie Inc. / EvolveImmune Therapeutics Inc. — 2024 · $1.5B · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / Ambrx Biopharma Inc. — 2024 · $2.0B · Mixed — partial payoff, real shortfalls.
• AbbVie Inc. / Aliada Therapeutics — 2024 · $1.4B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Novavax Inc. — 2024 · $1.2B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Modifi Biosciences — 2024 · $1.3B · Mixed — partial payoff, real shortfalls.
• Novartis AG / MorphoSys AG — 2024 · $2.9B · Underwhelmed — fell short of the thesis.
• Merck & Co. Inc. / LaNova Medicines Ltd. — 2024 · $3.3B
• Bristol-Myers Squibb Company / Repertoire Immune Medicines Inc. — 2024 · $1.9B
• Roche Holding AG / Ascidian Therapeutics Inc. — 2024 · $1.8B
• Organon & Co. / Dermavant Sciences Ltd. — 2024 · $1.2B
• Novo Nordisk A/S / Neomorph Inc. — 2024 · $1.5B
• Eli Lilly and Company / Radionetics Oncology Inc. — 2024 · $1.1B
• Novartis AG / Mariana Oncology Inc. — 2024 · $1.8B
• Pfizer Inc. / Triana Biomedicines Inc. — 2024 · $1.5B
• Hercules CM NewCo Inc. (Kailera Therapeutics) / Jiangsu Hengrui Pharmaceuticals Co. Ltd. — 2024 · $6.0B
• AstraZeneca PLC / CSPC Pharmaceutical Group Ltd. — 2024 · $2.0B
• Johnson & Johnson / Numab Therapeutics AG (Yellow Jersey Therapeutics) — 2024 · $1.2B
• Takeda Pharmaceutical Company Limited / Degron Therapeutics Ltd. — 2024 · $1.2B
• Merck & Co. Inc. / Curon Biopharmaceutical (Shanghai) Co. Ltd. — 2024 · $1.3B
• Genentech Inc. (Roche Holding AG) / Regor Pharmaceuticals Inc. — 2024 · $850M
• Takeda Pharmaceutical Company Limited / AC Immune SA — 2024 · $2.2B
• AbbVie Inc. / Celsius Therapeutics Inc. — 2024 · $250M
• BioNTech SE / Biotheus Inc. (Pumai Biotechnology) — 2024 · $950M
• GSK plc / CureVac N.V. — 2024 · $1.6B
• Eisai Co., Ltd. / SEED Therapeutics Inc. — 2024 · $1.5B
• Amneal Pharmaceuticals Inc. / Kashiv BioSciences LLC — 2024
• Eli Lilly and Company / HAYA Therapeutics SA — 2024 · $1.0B
• Otsuka Pharmaceutical Co., Ltd. / Jnana Therapeutics Inc. — 2024 · $1.1B
• Recordati S.p.A. / Sanofi SA — 2024 · $1.1B
• Incyte Corporation / Escient Pharmaceuticals Inc. — 2024 · $750M
• Bayer AG / Dewpoint Therapeutics Inc. — 2024 · $424M
• AbbVie Inc. / Landos Biopharma Inc. — 2024 · $212M
• Avenzo Therapeutics Inc. / VelaVigo Bio Inc. — 2024 · $800M
• Kyowa Kirin Co. Ltd. / Kura Oncology Inc. — 2024 · $1.5B
• AbbVie Inc. / FutureGen Biopharmaceutical (Shanghai) Co. Ltd. — 2024 · $1.7B
• Biogen Inc. / Neomorph Inc. — 2024 · $1.4B

← Deal Library  ·  Interactive search  ·  How we score deals